Rough road to development for neuroprotectants in acute stroke

Abstract

Although the results of recent studies of neuroprotective agents in acute stroke have been disappointing, researchers appear to be undeterred and further trials are underway. The lack of efficacy seen with agents such as tirilazad and lubeluzole may be dose related. The new studies have taken the recent findings into consideration and researchers are hoping that significant effects will be seen in subsequent trials. At the American Heart Association’s 21st International Joint Conference on Stroke and Cerebral Circulation [ San Antonio, Texas, US; January 1996 ], results from the latest investigations into a variety of neuroprotective agents were presented.